Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + oxycodone vs oxycodone for postoperative analgesia after esophageal/gastric ESD
ChiCTR2600115963Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in esophageal cancer, Esophageal epithelial dysplasia (EED), gastric cancer (GC) and 1 more comparing Dexmedetomidine + oxycodone with Oxycodone monotherapy (2 arms). Primary endpoint: 24-hour postoperative resting pain score. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dexmedetomidineoxycodone
03
Conditions
esophageal cancerEsophageal epithelial dysplasia (EED)gastric cancer (GC)gastric dysplasia
Beyond the preview
Go deeper on ChiCTR2600115963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115963.